You are here

MOR202

With no partner, MorphoSys drops MOR202 in myeloma

Biopharma Dive

Fri, 08/3/18 - 10:53 pm

anti-CD3 antibody

MorphoSys: That Celgene-abandoned cancer drug isn't dead yet

Fierce Biotech

Mon, 04/6/15 - 11:03 am

MorphoSys Rises on $818 Million Drug Alliance

Bloomberg

Thu, 06/27/13 - 10:41 am

Multiple Myeloma